AbInitio Bio
YC X26Boston, US · Founded 2026 · 2 employees · 1 known investors
AbInitio uses AI models to predict molecular properties, optimize bioprocess conditions, and recommend cell line and media selections for biopharmaceutical development. The company serves pharma and biotech teams to accelerate the path from drug candidate to commercial manufacturing scale.
Founders & leadership· Y Combinator alumni (X26)
Daniel Mukasain𝕏Founder & CEO
Nisha GopalinFounder